CN1283289C - Traditional Chinese medicine preparation for treating vertigo and preparation method thereof - Google Patents
Traditional Chinese medicine preparation for treating vertigo and preparation method thereof Download PDFInfo
- Publication number
- CN1283289C CN1283289C CN 200410074042 CN200410074042A CN1283289C CN 1283289 C CN1283289 C CN 1283289C CN 200410074042 CN200410074042 CN 200410074042 CN 200410074042 A CN200410074042 A CN 200410074042A CN 1283289 C CN1283289 C CN 1283289C
- Authority
- CN
- China
- Prior art keywords
- preparation
- solution
- parts
- adds
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 59
- 239000003814 drug Substances 0.000 title claims description 49
- 208000012886 Vertigo Diseases 0.000 title abstract description 5
- 231100000889 vertigo Toxicity 0.000 title abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 107
- 238000000034 method Methods 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000000706 filtrate Substances 0.000 claims description 25
- 208000002173 dizziness Diseases 0.000 claims description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 10
- 241000628997 Flos Species 0.000 claims description 9
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 230000003285 pharmacodynamic effect Effects 0.000 claims description 4
- 241000202807 Glycyrrhiza Species 0.000 claims description 2
- 241001421953 Eclipta <beetle> Species 0.000 claims 1
- 239000008187 granular material Substances 0.000 abstract description 46
- 238000003908 quality control method Methods 0.000 abstract description 22
- 239000000243 solution Substances 0.000 description 91
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 60
- 238000012360 testing method Methods 0.000 description 54
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
- 239000000463 material Substances 0.000 description 34
- 239000003826 tablet Substances 0.000 description 31
- 239000013558 reference substance Substances 0.000 description 30
- 239000000047 product Substances 0.000 description 28
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 26
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 26
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 26
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 26
- 229940025878 hesperidin Drugs 0.000 description 26
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 26
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 26
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 26
- 239000007788 liquid Substances 0.000 description 25
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- 239000002904 solvent Substances 0.000 description 16
- 239000007941 film coated tablet Substances 0.000 description 14
- 239000001768 carboxy methyl cellulose Substances 0.000 description 13
- 238000000605 extraction Methods 0.000 description 13
- 238000004809 thin layer chromatography Methods 0.000 description 13
- 239000004375 Dextrin Substances 0.000 description 12
- 229920001353 Dextrin Polymers 0.000 description 12
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 12
- 239000000853 adhesive Substances 0.000 description 12
- 230000001070 adhesive effect Effects 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 12
- 238000000576 coating method Methods 0.000 description 12
- 235000019425 dextrin Nutrition 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 12
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 12
- 239000002775 capsule Substances 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 239000013543 active substance Substances 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 239000000945 filler Substances 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 8
- 239000012567 medical material Substances 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 239000000825 pharmaceutical preparation Substances 0.000 description 8
- 239000012085 test solution Substances 0.000 description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- RZJRJXONCZWCBN-UHFFFAOYSA-N alpha-octadecene Natural products CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 6
- RZJRJXONCZWCBN-NJFSPNSNSA-N octadecane Chemical group CCCCCCCCCCCCCCCCC[14CH3] RZJRJXONCZWCBN-NJFSPNSNSA-N 0.000 description 6
- 229940038384 octadecane Drugs 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 238000011003 system suitability test Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 244000303040 Glycyrrhiza glabra Species 0.000 description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- UWUZCDRVSPBFDA-UHFFFAOYSA-N benzene;chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O.C1=CC=CC=C1 UWUZCDRVSPBFDA-UHFFFAOYSA-N 0.000 description 4
- SYWUAPJQKHSVPQ-UHFFFAOYSA-N benzene;ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O.C1=CC=CC=C1 SYWUAPJQKHSVPQ-UHFFFAOYSA-N 0.000 description 4
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 4
- 239000004518 granules dosage form Substances 0.000 description 4
- 235000011477 liquorice Nutrition 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- -1 sublimed preparation Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 244000286838 Eclipta prostrata Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010023567 Labyrinthitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 206010047348 Vertigo positional Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 201000000691 benign paroxysmal positional nystagmus Diseases 0.000 description 1
- 208000001870 benign paroxysmal positional vertigo Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 1
- 229960004536 betahistine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000860 cochlear nerve Anatomy 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- ZAVXXBAIPSQJGS-UHFFFAOYSA-B tetracalcium;tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ZAVXXBAIPSQJGS-UHFFFAOYSA-B 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 201000000200 vestibular neuronitis Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese medicinal preparation for treating vertigo and a quality control method thereof, in particular to a Chinese medicinal preparation for treating vertigo, which comprises a formula of tablets and granules and a new quality control method.
Description
Technical field:
The present invention relates to a kind of Chinese medicine pharmaceutical preparation and method of quality control thereof, particularly relate to a kind of Chinese medicine preparation for the treatment of dizziness and comprise the prescription of tablet and granule and new method of quality control.
Background technology:
Dizzy is (vestibule nuclear and contact path thereof, eye in internal ear, acoustic nerve, brain stem and the cerebellum) pathological changes or a kind of unusual sensation that rotatablely moves that dysfunction caused because organ of equilibration, and common forfeiture with equilibrium function.Primary disease belongs to Chinese medicine " dizzy " category.General clinical manifestation: the patient feels own and perhaps feels surrounding rotating around own round the surrounding motion, simultaneously with instability of gait, can not straight line moving, and lasting amesiality and nystagmus etc. during walking.Dizzy is common clinical symptoms, is found in multiple disease.As Meniere disease, vestibular neuronitis, acute festering type labyrinthitis, benign paroxysmal positional vertigo disease, central vertigo etc.The treatment of chemistry medicine can be adopted scopolamine, betahistine, dimenhydrinate, meclizine etc. according to the state of an illness, perhaps takes operative therapy.Generally can cause certain side effect.Chinese medicine is generally all taked determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs.
Preparation of the present invention is that Guilin Sanjin Group Guilin Sanjin Biological Pharmaceutical Limited Liability Company development a kind of treats dizzy Chinese medicine, finished product comprises tablet, two kinds of dosage forms of granule, every bag heavy 8g of granule, tablet: every heavy 0.31g of Film coated tablets, every heavy 0.25g of the plain sheet of coated tablet, the therapeutic effect of two kinds of dosage forms is similar, is invigorating spleen to remove dampness, liver-kidney tonifying.Be used for stagnation of phlegm-damp in middle-JIAO, the giddy that deficiency of the liver and kindey causes, dizziness.Method of quality control is identical.
Preparation of the present invention is as Chinese medicine preparation, and prescription is unique, has good therapeutic effect, but difficult quality control need find a kind of suitable method of quality control to determine the quality of product, and the present invention just provides the prescription and the method for quality control of said preparation.The said preparation prescription is guidance with the Chinese medical theory, and is scientific and reasonable based on clinical practice, and determined curative effect is stable and controllable for quality, no obvious toxic-side effects.
This method of quality control is comparatively perfect, strong operability, and favorable reproducibility, measurement deviation is little, good stability, precision height.
Summary of the invention:
The invention provides a kind of Chinese medicine preparation for the treatment of dizziness and comprise the prescription of tablet and granule and new method of quality control.Chinese medicine preparation of the present invention is processed into by the raw material of Chinese medicine process of following prescription.
Rhizoma Alismatis 100-550 part Rhizoma Atractylodis Macrocephalae 50-320 part Poria 50-340 part Pericarpium Citri Reticulatae 40-250 part
Rhizoma Pinelliae 60-310 part Fructus Ligustri Lucidi 80-450 part Herba Ecliptae 70-460 part Flos Chrysanthemi 80-420 part
Radix Achyranthis Bidentatae 50-360 part Radix Glycyrrhizae 40-250 part
Preferred prescription consists of:
Rhizoma Alismatis 150-350 part Rhizoma Atractylodis Macrocephalae 80-220 part Poria 80-220 part Pericarpium Citri Reticulatae 50-150 part Rhizoma Pinelliae Preparata 80-210 part Fructus Ligustri Lucidi 90-250 part Herba Ecliptae 90-260 part Flos Chrysanthemi 150-220 part Radix Achyranthis Bidentatae 80-160 part Radix Glycyrrhizae 40-150 part
Most preferred prescription consists of:
125 parts of 187.5 parts of Pericarpium Citri Reticulataes of 187.5 parts of Poria of 312.5 parts of Rhizoma Atractylodis Macrocephalaes of Rhizoma Alismatis
225 parts of Flos Chrysanthemi 200g of 225 portions of Herba Ecliptaes of 187.5 parts of Fructus Ligustri Lucidi of the Rhizoma Pinelliae
100 parts in 125 portions of Radix Glycyrrhizaes of Radix Achyranthis Bidentatae
In more than forming, every part of representative be weight portion, weight is calculated with crude drug, and as if being unit with the gram, more than composition can be made into 1000 doses of pharmaceutical preparatioies, described 1000 doses of fingers, the final drug preparation of making, as make 1000 of capsule preparations, 1000 in tablet, oral liquid 1000ml, granule 1000g etc. can make big packing as granule, as the 100-500 bag, specifically can be 100 bags, 125 bags, 200 bags, 250 bags, 500 bags etc., every bag can be used as taking dose 1 time, and oral liquid can be made Different Package such as 5ml/ bottle, 200ml/ bottle, the 100ml/ bottle, the 50ml/ bottle.
More than form, as if being unit with the gram, can be made into the preparation of 50-1000 taking dose, as tablet, make 1000, each taking dose can be the 1-20 sheet, can take 50-1000 time altogether.As granule, make 100 bags, take the 1-2 bag at every turn, can take 50-100 time altogether.
More than form to be by weight as proportioning, when producing, can increase or reduce according to corresponding proportion, as large-scale production can be unit with the kilogram, or be unit with the ton, small-scale production also can restrain and be unit, weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, and is fat or modest as serious symptom or light disease for especial patient, and the proportioning of the amount of can corresponding adjustment forming increases or reduce being no more than 100%, and drug effect is constant.
Raw material of Chinese medicine, especially ministerial drug and adjuvant drug in more than forming also can be replaced by the suitable Chinese medicine with identical property of medicine, and its drug effect of the Chinese medicine preparation after the replacement is constant.
Chinese medicine preparation of the present invention is to process through extraction or other modes by the raw material of Chinese medicine that above-mentioned prescription is formed, and makes pharmaceutically active substance, subsequently, with this active substance is raw material, adds the medicine acceptable carrier when needing, and makes pharmaceutical preparation according to the routine techniques of galenic pharmacy.Described active substance can obtain by extracting raw material of Chinese medicine respectively, also can obtain by the co-extracted raw material of Chinese medicine, also can obtain by other modes, as: by pulverize, squeeze, calcine, grind, sieve, percolation, extraction, water are carried, alcohol extraction, ester are carried, methods such as ketone is carried, chromatography obtain, these active substances can be the material of extractum form, can be that dry extract also can be a fluid extract, make different concentration according to the different needs decision of preparation.
Pharmaceutically active substance in the pharmaceutical preparation of the present invention, its shared percentage by weight in preparation can be 0.1-99.9%, all the other are the medicine acceptable carrier.Pharmaceutical preparation of the present invention exists with unit dosage form, and described unit dosage form is meant the unit of preparation, as every of tablet, capsular every capsules, every of injection etc., in the unit dose, the amount that contains active substance is 5-800mg, preferably 50-500mg.
Pharmaceutical preparation of the present invention can be any pharmaceutically useful dosage form, these dosage forms comprise: tablet, capsule, oral liquid, syrup, granule, pill, powder, unguentum, sublimed preparation, injection, suppository, spray, drop pill, patch, slow releasing preparation, controlled release preparation, capsule preferably, granule.
Pharmaceutical preparation of the present invention, the preparation of its oral administration can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet in case of necessity.
The filler that is suitable for comprises cellulose, mannitol, lactose and other similar filler.Suitable disintegrating agent comprises starch, cellulose derivative, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant comprises, for example magnesium stearate.The acceptable wetting agent of appropriate drug comprises sodium lauryl sulphate.
Can fill by mixing, the method that tabletting etc. are commonly used prepares solid oral composition.Mix repeatedly active substance is distributed in those compositionss of a large amount of filleies of whole use.
The form of oral liquid for example can be aqueous or oily suspensions, solution, Emulsion, syrup or elixir, perhaps can be a kind of available water before use or other suitable composite dry products of carrier.This liquid preparation can contain conventional additive, such as suspending agent, for example sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl-cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenation edible fat, emulsifying agent, for example lecithin, anhydro sorbitol monooleate or arabic gum; Non-aqueous carrier (they can comprise edible oil), for example almond oil, fractionated coconut oil, such as oily ester, propylene glycol or the ethanol of the ester of glycerol; Antiseptic, for example para hydroxybenzene methyl ester or propyl p-hydroxybenzoate or sorbic acid, and if desired, can contain conventional flavouring agent or coloring agent.
For injection, the liquid unit dosage forms of preparation contains active substance of the present invention and sterile carrier.According to carrier and concentration, this chemical compound can be suspended or dissolving.The preparation of solution is normally by being dissolved in active substance in a kind of carrier filter-sterilized before it is packed into a kind of suitable bottle or ampoule, sealing then.For example a kind of local anesthetic of adjuvant, antiseptic and buffer agent also can be dissolved in this carrier.In order to improve its stability, can be after the bottle of packing into that this compositions is freezing, and under vacuum, water is removed.
Pharmaceutical preparation of the present invention, when being prepared into medicament, optionally add suitable medicine acceptable carrier, described medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, the EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Pharmaceutical preparation of the present invention, particularly capsule are determined usage and dosage according to patient's situation in use, but obey 1-4 time every day, each 1-20 agent, as: 1-20 grain or sheet.
Preparation of the present invention, can adopt following method preparation:
More than ten the flavor medicines, decoct with water 2 times, 0.5-3 hour for the first time, the 2nd time 0.5-2.5 hour, collecting decoction filtered, filtrate is concentrated into relative density 1.05-1.30 (30-90 degree centigrade), add 1-3 and doubly measure ethanol, get supernatant and reclaim ethanol, be condensed into relative density 1.20-1.50 (40-90 degree centigrade) clear paste.Granule: qinghuo reagent adds right amount of auxiliary materials such as dextrin, sucrose, makes granule, drying, and packing is promptly.
Tablet: qinghuo reagent adds right amount of auxiliary materials such as dextrin, Pulvis Talci, magnesium stearate, makes granule, tabletting, promptly.
Capsule: qinghuo reagent adds right amount of auxiliary materials such as dextrin, makes granule, and is encapsulated, promptly.
Also can make any dosage form on the pharmaceutics, as comprise granule, tablet, syrup, oral liquid, drop pill, powder, pill, unguentum, injection etc.
Chinese medicine preparation of the present invention, function cure mainly and are invigorating spleen to remove dampness, liver-kidney tonifying.Be used for stagnation of phlegm-damp in middle-JIAO, the giddy that deficiency of the liver and kindey causes, dizziness.
Chinese medicine preparation of the present invention, pharmacodynamics test show that mice is had good analgesic activity; Make the movable minimizing of mice, escalated dose does not cause sleep yet; Can strengthen the hypnotic effect of chloral hydrate, ethanol; Middle mediator measurement result, this medicine can make rat whole brain norepinephrine, dopamine obviously increase, and simultaneously visible 5-hydroxy tryptamine slightly increases; To normal Canis familiaris L. and pathologic Hypertensive Rats, this medicine presents obvious blood pressure lowering effect; At the whole animal and the myenteron that exsomatizes, has the effect of direct inhibition myenteron; The experiment of rat albumen arthritis shows that this medical instrument has good antiinflammation; Can obviously improve simultaneously the equilibrium function of cerebral ischemic model mice and mice vertigo.
Chinese medicine preparation of the present invention, toxicological test is the result show, this medicine is to mice lavage LD
50Be 481.4g/kg, be equivalent to 1600 times of human oral (1 time) dosage approximately; Gavage heavy dose continuously and (be equivalent to 1/3LD
50) this product 21 days, there is no tangible toxic reaction and delay toxic reaction, hepatic and renal function is not had tangible detrimental effect.
Chinese medicine preparation of the present invention, through first Affiliated Hospital of Colleges Of Traditional Chinese Medicine Of Guangxi, three tame hospitals such as second Affiliated Hospital of Colleges Of Traditional Chinese Medicine Of Guangxi and The People's Hospital, Guangxi Zhuang Autonomous Region, with Herb Gynostemmae Pentaphylli total glycosides tablet (stagnation of turbid phlegm in middle-JIAO card), QIJU DIHUANG WAN (deficiecny of liver-YIN card) compares, dizzy to the stagnation of turbid phlegm in middle-JIAO card, dizzy clinical verification 300 examples of carrying out of deficiecny of liver-YIN card, wherein 2000 examples are organized in treatment, matched group 120 examples, Clinical results shows that this product total effective rate is 91.3%, the matched group effective percentage is 90.8%, two groups of contrast there was no significant differences, prompting this product is dizzy to the stagnation of turbid phlegm in middle-JIAO card, deficiency of the liver and kindey is demonstrate,proved the dizzy clinical efficacy preferably that has.Different pattern of syndrome curative effect comparative results show, dizzy and the deficiency of the liver and kindey of stagnation of turbid phlegm in middle-JIAO card is demonstrate,proved dizzy matched group and treatment group curative effect there was no significant difference, and the clinical symptoms efficacy result shows clinical symptoms that this product can obviously improve various because stagnation of turbid phlegm in middle-JIAO, deficiency of the liver and kindey and cause, similar to matched group.Clinical research has been carried out blood, just routine examination to 300 routine patients, and tangible untoward reaction and toxic and side effects are not all found in the darling renal function inspection, and prompting this product is safe and reliable.
The present invention also provides a kind of method of quality control of XUANYUNNING preparation, and this method can be held the quality of relevant medicine more accurately, reduces drug risk, improves the quality of products.
The method of quality control of XUANYUNNING preparation provided by the invention, the particularly particulate method of quality control of XUANYUNNING sheet and XUANYUNNING can be described below:
3 of Film coated tablets are got in discriminating (1), remove coating, porphyrize, perhaps get granule 5g, add water 15ml, jolting makes dissolving, place, get supernatant and add ethyl acetate 30ml jolting extraction, extracting solution is added on neutral alumina post (10g, 200～300 orders, internal diameter 1.5cm) on, with ethyl acetate 20ml eluting, collect eluent, evaporate to dryness, residue add ethyl acetate 1ml makes dissolving, as need testing solution.Other gets Rhizoma Atractylodis Macrocephalae control medicinal material 0.9g, decocts with water 1 hour, filters, and filtrate is concentrated into about 10ml, adds ethyl acetate 20ml and extracts, and extracting solution evaporate to dryness, residue add ethyl acetate 1ml makes dissolving, in contrast medical material solution.According to thin layer chromatography (2000 version " Chinese pharmacopoeia appendix VI B) test, draw each 6 μ l of above-mentioned two kinds of solution, put respectively in same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, with normal hexane-ethyl acetate (1: 1) is developing solvent, launch, take out, dry, put in the ammonia steam smoked after, put again under the ultraviolet light (365nm) and inspect.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color.(2) get 10 of this product Film coated tablets, remove coating, porphyrize, or get granule 16g, add ethanol 50ml, reflux 40 minutes, filter, filtrate adds hydrochloric acid 1ml, and reflux is concentrated into about 5ml after 1 hour, add water 10ml, extract with petroleum ether (60 ~ 90 ℃) 30ml jolting, divide and get petroleum ether liquid, evaporate to dryness, residue adds ethanol 1ml makes dissolving, as need testing solution.Other evens up pier fruit acid reference substance, adds ethanol and makes the solution that every 1ml contains 1mg, product in contrast.According to thin layer chromatography (2000 version " Chinese pharmacopoeia appendix VI B) test, draw test solution 6 μ l, reference substance solution 2 μ l, put respectively in same be on the silica gel H lamellae of adhesive with the sodium carboxymethyl cellulose, with chloroform-methanol (40: 1) is developing solvent, launch, take out, dry, spray is with the phosphomolybdic acid test solution, and it is clear to be heated to the speckle colour developing at 110 ℃.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
(3) get 20 of this product Film coated tablets, or get granule 32g, porphyrize, the 50ml that adds diethyl ether, reflux 1 hour filters, and filtrate evaporate to dryness, residue add ethanol 0.5ml makes dissolving, as need testing solution.Extracting liquorice control medicinal material 3.2g decocts with water 1 hour in addition, filters, and filtrate is concentrated into about 2ml, add ethanol 5ml and stir, filter, filtrate evaporate to dryness, residue add water 5ml makes dissolving, the 10ml jolting that adds diethyl ether is extracted, and extracting solution evaporate to dryness, residue add ethanol 2ml makes dissolving, in contrast medical material solution.According to thin layer chromatography (2000 version " Chinese pharmacopoeia appendix VI B) test, draw need testing solution 10 μ l, control medicinal material solution 4 μ l, put respectively in without activatory same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, be developing solvent with normal hexane-benzene-ethyl acetate (14: 1: 5) earlier, launch 8cm, taking out, dry, is developing solvent with positive benzene-ethyl acetate-chloroform (14: 3: 6) again, launch 8cm, take out, dry, put under the ultra-violet lamp (365nm) and inspect.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color.
Check: should meet every regulation relevant under the tablet item (2000 version " Chinese pharmacopoeia appendix I D), relevant every regulation under the granule agent item (" Chinese pharmacopoeia appendix I C).
Assay: measure according to high performance liquid chromatography (2000 version " Chinese pharmacopoeia appendix VI D).
Chromatographic condition and system suitability test are filler with the octadecane bonded silica gel: methanol-water (40: 60) is a mobile phase; The detection wavelength is 286nm.Number of theoretical plate calculates by the Hesperidin peak should be not less than 3000.
It is an amount of that the preparation precision of reference substance solution takes by weighing the Hesperidin reference substance, adds Methanamide and make the solution that every 1ml contains 50 μ g, promptly.
20 of this product are got in the preparation of need testing solution, remove coating, perhaps get the granule of content uniformity item, mixing, porphyrize is got 2g, and accurate the title decided porphyrize, get 1.5g, the accurate title, decide, and puts in the apparatus,Soxhlet's, it is an amount of to add methanol, and heating extraction liquid is colourless, puts cold, extracting solution is recycled to dried, adds Methanamide and makes dissolving, is transferred in the 25ml measuring bottle, add Methanamide and put scale, shake up, promptly.
Accurate respectively reference substance solution and each the 10 μ l of need testing solution of drawing of algoscopy inject chromatograph of liquid, measure.Promptly.
Every of this product contains Pericarpium Citri Reticulatae with Hesperidin (C
28H
34O
15) meter, coated tablet must not be less than 0.15mg, and Film coated tablets must not be less than 0.30mg.The granule dosage form must not be less than 2.0mg for every bag.
Method of quality control provided by the invention is characterized in that, comprises discriminating, checks the step of assay.
Method of quality control provided by the invention is characterized in that, the step of described assay is to measure the step of Determination of Hesperidin Content in the preparation.
Described Hesperidin has following structure:
(C
28H
34O
15)
Method of quality control provided by the invention is characterized in that, comprises the step of measuring Determination of Hesperidin Content with high performance liquid chromatography (HPLC).
Method of quality control provided by the invention, it is characterized in that, in the described step with the high effective liquid chromatography for measuring content of hesperidin, the chromatographic condition of employing and system suitability test, be filler with the octadecane bonded silica gel: methanol-water (40: 60) is a mobile phase; The detection wavelength is 286nm.Number of theoretical plate calculates by the Hesperidin peak should be not less than 3000.
Method of quality control provided by the invention is characterized in that, in the described step with the high effective liquid chromatography for measuring content of hesperidin, following method is adopted in the preparation of reference substance solution, it is an amount of that precision takes by weighing the Hesperidin reference substance, adds Methanamide and make the solution that every 1ml contains 50 μ g, promptly.
Method of quality control provided by the invention is characterized in that, in the described step with the high effective liquid chromatography for measuring content of hesperidin, following method is adopted in the preparation of need testing solution, gets 20 in tablet, removes coating, perhaps get the granule of content uniformity item, mixing, porphyrize, get 2g, the accurate title, decided porphyrize, get 1.5g, the accurate title, decide, and puts in the apparatus,Soxhlet's, and it is an amount of to add methanol, heating extraction liquid is colourless, put coldly, extracting solution is recycled to dried, adds Methanamide and makes dissolving, be transferred in the 25ml measuring bottle, add Methanamide and put scale, shake up, promptly.
Method of quality control provided by the invention is characterized in that, assay adopts following method in the step that described Determination of Hesperidin Content is measured, and accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing inject chromatograph of liquid, measure.Promptly.Every of this product contains Pericarpium Citri Reticulatae with Hesperidin (C
28H
34O
15) meter, coated tablet must not be less than 0.15mg, and Film coated tablets must not be less than 0.30mg.The granule dosage form must not be less than 2.0mg for every bag.
Method of quality control provided by the invention is characterized in that, assay adopts following method in the step that described content of hesperidin is measured,
Assay: measure according to high performance liquid chromatography (2000 version " Chinese pharmacopoeia appendix VI D).
Chromatographic condition and system suitability test are filler with the octadecane bonded silica gel: methanol-water (40: 60) is a mobile phase; The detection wavelength is 286nm.Number of theoretical plate calculates by the Hesperidin peak should be not less than 3000.
It is an amount of that the preparation precision of reference substance solution takes by weighing the Hesperidin reference substance, adds Methanamide and make the solution that every 1ml contains 50 μ g, promptly.
20 of this product are got in the preparation of need testing solution, remove coating, perhaps get the granule of content uniformity item, mixing, porphyrize is got 2g, and accurate the title decided porphyrize, get 1.5g, the accurate title, decide, and puts in the apparatus,Soxhlet's, it is an amount of to add methanol, and heating extraction liquid is colourless, puts cold, extracting solution is recycled to dried, adds Methanamide and makes dissolving, is transferred in the 25ml measuring bottle, add Methanamide and put scale, shake up, promptly.
Accurate respectively reference substance solution and each the 10 μ l of need testing solution of drawing of algoscopy inject chromatograph of liquid, measure.Promptly.
Every of this product contains Pericarpium Citri Reticulatae with Hesperidin (C
28H
34O
15) meter, coated tablet must not be less than 0.15mg, and Film coated tablets must not be less than 0.30mg.The granule dosage form must not be less than 2.0mg for every bag.
Above method not only can detect the XUANYUNNING sheet, also can detect any other dosage form of XUANYUNNING preparation, as: film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.Preparation of the present invention, peroral dosage form preferably, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.Characteristics of the present invention are:
1, this method precision, repeatability, good stability.
2, overcome the existing color instability of original thin layer chromatography scanning, deficiency that measurement deviation is big.
3, this method helps the quality control of XUANYUNNING sheet, XUANYUNNING granule series of products and other dosage forms more.
The specific embodiment:
By the following examples, further specify the present invention.
Embodiment 1, the detection of Film coated tablets
3 of Film coated tablets are got in discriminating (1), remove coating, porphyrize, add water 15ml, jolting makes dissolving, places, get supernatant and add ethyl acetate 30ml jolting extraction, extracting solution is added on neutral alumina post (10g, 200～300 orders, internal diameter 1.5cm) on, with ethyl acetate 20ml eluting, collect eluent, evaporate to dryness, residue adds ethyl acetate 1ml makes dissolving, as need testing solution.Other gets Rhizoma Atractylodis Macrocephalae control medicinal material 0.9g, decocts with water 1 hour, filters, and filtrate is concentrated into about 10ml, adds ethyl acetate 20ml and extracts, and extracting solution evaporate to dryness, residue add ethyl acetate 1ml makes dissolving, in contrast medical material solution.According to thin layer chromatography (2000 version " Chinese pharmacopoeia appendix VI B) test, draw each 6 μ l of above-mentioned two kinds of solution, put respectively in same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, with normal hexane-ethyl acetate (1: 1) is developing solvent, launch, take out, dry, put in the ammonia steam smoked after, put again under the ultraviolet light (365nm) and inspect.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color.
(2) get 10 of this product Film coated tablets, remove coating, porphyrize, add ethanol 50ml, reflux 40 minutes filters, filtrate adds hydrochloric acid 1ml, reflux is concentrated into about 5ml after 1 hour, add water 10ml, extracts with petroleum ether (60 ~ 90 ℃) 30ml jolting, divide and get petroleum ether liquid, evaporate to dryness, residue add ethanol 1ml makes dissolving, as need testing solution.Other evens up pier fruit acid reference substance, adds ethanol and makes the solution that every 1ml contains 1mg, product in contrast.According to thin layer chromatography (2000 version " Chinese pharmacopoeia appendix VI B) test, draw test solution 6 μ l, reference substance solution 2 μ l, put respectively in same be on the silica gel H lamellae of adhesive with the sodium carboxymethyl cellulose, with chloroform-methanol (40: 1) is developing solvent, launch, take out, dry, spray is with the phosphomolybdic acid test solution, and it is clear to be heated to the speckle colour developing at 110 ℃.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
(3) get 20 of this product Film coated tablets, porphyrize, the 50ml that adds diethyl ether, reflux 1 hour filters, and filtrate evaporate to dryness, residue add ethanol 0.5ml makes dissolving, as need testing solution.Extracting liquorice control medicinal material 3.2g decocts with water 1 hour in addition, filters, and filtrate is concentrated into about 2ml, add ethanol 5ml and stir, filter, filtrate evaporate to dryness, residue add water 5ml makes dissolving, the 10ml jolting that adds diethyl ether is extracted, and extracting solution evaporate to dryness, residue add ethanol 2ml makes dissolving, in contrast medical material solution.According to thin layer chromatography (2000 version " Chinese pharmacopoeia appendix VIB) test, draw need testing solution 10 μ l, control medicinal material solution 4 μ l, put respectively in without activatory same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, be developing solvent with normal hexane-benzene-ethyl acetate (14: 1: 5) earlier, launch 8cm, taking out, dry, is developing solvent with positive benzene-ethyl acetate-chloroform (14: 3: 6) again, launch 8cm, take out, dry, put under the ultra-violet lamp (365nm) and inspect.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color.
Check: should meet every regulation relevant under the tablet item (2000 version " Chinese pharmacopoeia appendix I D), relevant every regulation under the granule agent item (" Chinese pharmacopoeia appendix I C).
Assay: measure according to high performance liquid chromatography (2000 version " Chinese pharmacopoeia appendix VI D).
Chromatographic condition and system suitability test are filler with the octadecane bonded silica gel: methanol-water (40: 60) is a mobile phase; The detection wavelength is 286nm.Number of theoretical plate calculates by the Hesperidin peak should be not less than 3000.
It is an amount of that the preparation precision of reference substance solution takes by weighing the Hesperidin reference substance, adds Methanamide and make the solution that every 1ml contains 50 μ g, promptly.
20 of Film coated tablets are got in the preparation of need testing solution, remove coating, mixing, porphyrize, get 2g, the accurate title, decided porphyrize, get 1.5g, the accurate title, decide, and puts in the apparatus,Soxhlet's, it is an amount of to add methanol, and heating extraction liquid is colourless, puts cold, extracting solution is recycled to dried, adds Methanamide and makes dissolving, is transferred in the 25ml measuring bottle, add Methanamide and put scale, shake up, promptly.
Accurate respectively reference substance solution and each the 10 μ l of need testing solution of drawing of algoscopy inject chromatograph of liquid, measure.Promptly.
Every of this product contains Pericarpium Citri Reticulatae with Hesperidin (C
28H
34O
15) meter, Film coated tablets must not be less than 0.30mg.
Embodiment 2, the detection of granule
Granule 5g is got in discriminating (1), adds water 15ml, and jolting makes dissolving, place, get supernatant and add ethyl acetate 30ml jolting extraction, extracting solution is added on neutral alumina post (10g, 200～300 orders, internal diameter 1.5cm) on, with ethyl acetate 20ml eluting, collect eluent, evaporate to dryness, residue adds ethyl acetate 1ml makes dissolving, as need testing solution.Other gets Rhizoma Atractylodis Macrocephalae control medicinal material 0.9g, decocts with water 1 hour, filters, and filtrate is concentrated into about 10ml, adds ethyl acetate 20ml and extracts, and extracting solution evaporate to dryness, residue add ethyl acetate 1ml makes dissolving, in contrast medical material solution.According to thin layer chromatography (2000 version " Chinese pharmacopoeia appendix VI B) test, draw each 6 μ l of above-mentioned two kinds of solution, put respectively in same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, with normal hexane-ethyl acetate (1: 1) is developing solvent, launch, take out, dry, put in the ammonia steam smoked after, put again under the ultraviolet light (365nm) and inspect.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color.
(2) get granule 16g, add ethanol 50ml, reflux 40 minutes filters, filtrate adds hydrochloric acid 1ml, and reflux is concentrated into about 5ml after 1 hour, add water 10ml, extracts with petroleum ether (60 ~ 90 ℃) 30ml jolting, divide and get petroleum ether liquid, evaporate to dryness, residue add ethanol 1ml makes dissolving, as need testing solution.Other evens up pier fruit acid reference substance, adds ethanol and makes the solution that every 1ml contains 1mg, product in contrast.According to thin layer chromatography (2000 version " Chinese pharmacopoeia appendix VI B) test, draw test solution 6 μ l, reference substance solution 2 μ l, put respectively in same be on the silica gel H lamellae of adhesive with the sodium carboxymethyl cellulose, with chloroform-methanol (40: 1) is developing solvent, launch, take out, dry, spray is with the phosphomolybdic acid test solution, and it is clear to be heated to the speckle colour developing at 110 ℃.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
(3) get granule 32g, porphyrize, the 50ml that adds diethyl ether, reflux 1 hour filters, and filtrate evaporate to dryness, residue add ethanol 0.5ml makes dissolving, as need testing solution.Extracting liquorice control medicinal material 3.2g decocts with water 1 hour in addition, filters, and filtrate is concentrated into about 2ml, add ethanol 5ml and stir, filter, filtrate evaporate to dryness, residue add water 5ml makes dissolving, the 10ml jolting that adds diethyl ether is extracted, and extracting solution evaporate to dryness, residue add ethanol 2ml makes dissolving, in contrast medical material solution.According to thin layer chromatography (2000 version " Chinese pharmacopoeia appendix VI B) test, draw need testing solution 10 μ l, control medicinal material solution 4 μ l, put respectively in without activatory same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, be developing solvent with normal hexane-benzene-ethyl acetate (14: 1: 5) earlier, launch 8cm, taking out, dry, is developing solvent with positive benzene-ethyl acetate-chloroform (14: 3: 6) again, launch 8cm, take out, dry, put under the ultra-violet lamp (365nm) and inspect.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color.
Check: should meet every regulation relevant under the granule item (2000 version " Chinese pharmacopoeia appendix I D), relevant every regulation under the granule agent item (" Chinese pharmacopoeia appendix I C).
Assay: measure according to high performance liquid chromatography (2000 version " Chinese pharmacopoeia appendix VI D).
Chromatographic condition and system suitability test are filler with the octadecane bonded silica gel: methanol-water (40: 60) is a mobile phase; The detection wavelength is 286nm.Number of theoretical plate calculates by the Hesperidin peak should be not less than 3000.
It is an amount of that the preparation precision of reference substance solution takes by weighing the Hesperidin reference substance, adds Methanamide and make the solution that every 1ml contains 50 μ g, promptly.
The granule of content uniformity item, mixing, porphyrize are got in the preparation of need testing solution, get 2g, the accurate title, decided porphyrize, get 1.5g, the accurate title, decide, and puts in the apparatus,Soxhlet's, it is an amount of to add methanol, and heating extraction liquid is colourless, puts cold, extracting solution is recycled to dried, adds Methanamide and makes dissolving, is transferred in the 25ml measuring bottle, add Methanamide and put scale, shake up, promptly.
Accurate respectively reference substance solution and each the 10 μ l of need testing solution of drawing of algoscopy inject chromatograph of liquid, measure.Promptly.
Every of this product contains Pericarpium Citri Reticulatae with Hesperidin (C
28H
34O
15) meter, the granule dosage form must not be less than 2.0mg for every bag.
Embodiment 3, the detection of coated tablet
3 of coated tablets are got in discriminating (1), remove coating, porphyrize, add water 15ml, jolting makes dissolving, places, get supernatant and add ethyl acetate 30ml jolting extraction, extracting solution is added on neutral alumina post (10g, 200～300 orders, internal diameter 1.5cm) on, with ethyl acetate 20ml eluting, collect eluent, evaporate to dryness, residue adds ethyl acetate 1ml makes dissolving, as need testing solution.Other gets Rhizoma Atractylodis Macrocephalae control medicinal material 0.9g, decocts with water 1 hour, filters, and filtrate is concentrated into about 10ml, adds ethyl acetate 20ml and extracts, and extracting solution evaporate to dryness, residue add ethyl acetate 1ml makes dissolving, in contrast medical material solution.According to thin layer chromatography (2000 version " Chinese pharmacopoeia appendix VI B) test, draw each 6 μ l of above-mentioned two kinds of solution, put respectively in same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, with normal hexane-ethyl acetate (1: 1) is developing solvent, launch, take out, dry, put in the ammonia steam smoked after, put again under the ultraviolet light (365nm) and inspect.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color.
(2) get 10 of this product coated tablets, remove coating, porphyrize, add ethanol 50ml, reflux 40 minutes filters, filtrate adds hydrochloric acid 1ml, reflux is concentrated into about 5ml after 1 hour, add water 10ml, extracts with petroleum ether (60 ~ 90 ℃) 30ml jolting, divide and get petroleum ether liquid, evaporate to dryness, residue add ethanol 1ml makes dissolving, as need testing solution.Other evens up pier fruit acid reference substance, adds ethanol and makes the solution that every 1ml contains 1mg, product in contrast.According to thin layer chromatography (2000 version " Chinese pharmacopoeia appendix VI B) test, draw test solution 6 μ l, reference substance solution 2 μ l, put respectively in same be on the silica gel H lamellae of adhesive with the sodium carboxymethyl cellulose, with chloroform-methanol (40: 1) is developing solvent, launch, take out, dry, spray is with the phosphomolybdic acid test solution, and it is clear to be heated to the speckle colour developing at 110 ℃.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
(3) get 20 of this product coated tablets, porphyrize, the 50ml that adds diethyl ether, reflux 1 hour filters, and filtrate evaporate to dryness, residue add ethanol 0.5ml makes dissolving, as need testing solution.Extracting liquorice control medicinal material 3.2g decocts with water 1 hour in addition, filters, and filtrate is concentrated into about 2ml, add ethanol 5ml and stir, filter, filtrate evaporate to dryness, residue add water 5ml makes dissolving, the 10ml jolting that adds diethyl ether is extracted, and extracting solution evaporate to dryness, residue add ethanol 2ml makes dissolving, in contrast medical material solution.According to thin layer chromatography (2000 version " Chinese pharmacopoeia appendix VIB) test, draw need testing solution 10 μ l, control medicinal material solution 4 μ l, put respectively in without activatory same be on the silica gel g thin-layer plate of adhesive with the sodium carboxymethyl cellulose, be developing solvent with normal hexane-benzene-ethyl acetate (14: 1: 5) earlier, launch 8cm, taking out, dry, is developing solvent with positive benzene-ethyl acetate-chloroform (14: 3: 6) again, launch 8cm, take out, dry, put under the ultra-violet lamp (365nm) and inspect.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color.
Check: should meet every regulation relevant under the tablet item (2000 version " Chinese pharmacopoeia appendix I D), relevant every regulation under the granule agent item (" Chinese pharmacopoeia appendix I C).
Assay: measure according to high performance liquid chromatography (2000 version " Chinese pharmacopoeia appendix VI D).
Chromatographic condition and system suitability test are filler with the octadecane bonded silica gel: methanol-water (40: 60) is a mobile phase; The detection wavelength is 286nm.Number of theoretical plate calculates by the Hesperidin peak should be not less than 3000.
It is an amount of that the preparation precision of reference substance solution takes by weighing the Hesperidin reference substance, adds Methanamide and make the solution that every 1ml contains 50 μ g, promptly.
20 of coated tablets are got in the preparation of need testing solution, remove coating, mixing, porphyrize, get 2g, the accurate title, decided porphyrize, get 1.5g, the accurate title, decide, and puts in the apparatus,Soxhlet's, it is an amount of to add methanol, and heating extraction liquid is colourless, puts cold, extracting solution is recycled to dried, adds Methanamide and makes dissolving, is transferred in the 25ml measuring bottle, add Methanamide and put scale, shake up, promptly.
Accurate respectively reference substance solution and each the 10 μ l of need testing solution of drawing of algoscopy inject chromatograph of liquid, measure.Promptly.
Every of this product contains Pericarpium Citri Reticulatae with Hesperidin (C
28H
34O
15) meter, coated tablet must not be less than 0.15mg.
Embodiment 4
Rhizoma Alismatis 312.5g Rhizoma Atractylodis Macrocephalae 187.5g Poria 187.5g Pericarpium Citri Reticulatae 125g
Rhizoma Pinelliae 187.5g Fructus Ligustri Lucidi 225g Herba Ecliptae 225g Flos Chrysanthemi 200g
Radix Achyranthis Bidentatae 125g Radix Glycyrrhizae 100g
More than ten flavor medicines, decoct with water 2 times, 3 hours for the first time, the 2nd time 2.5 hours, collecting decoction filtered, filtrate is concentrated into relative density 1.2 (60 degrees centigrade), adds 3 times of amount ethanol, gets supernatant and reclaims ethanol, is condensed into relative density 1.50 (90 degrees centigrade) clear paste.
Granule: qinghuo reagent adds right amount of auxiliary materials such as dextrin, sucrose, makes granule, drying, and packing is promptly.
Tablet: qinghuo reagent adds right amount of auxiliary materials such as dextrin, Pulvis Talci, magnesium stearate, makes granule, tabletting, promptly.
Capsule: qinghuo reagent adds right amount of auxiliary materials such as dextrin, makes granule, and is encapsulated, promptly.
Embodiment 5
Rhizoma Alismatis 100g Rhizoma Atractylodis Macrocephalae 50g Poria 50g Pericarpium Citri Reticulatae 40g Rhizoma Pinelliae 60g Fructus Ligustri Lucidi 80g Herba Ecliptae 70g Flos Chrysanthemi 80g Radix Achyranthis Bidentatae 50g Radix Glycyrrhizae 40g
More than ten flavor medicines, decoct with water 2 times, 0.5 hour for the first time, the 2nd time 0.5 hour, collecting decoction filters, and filtrate is concentrated into relative density 1.05 (30 degrees centigrade), add 1 times of amount ethanol, get supernatant and reclaim ethanol, be condensed into relative density 1.20 (40 degrees centigrade) clear paste.Granule: qinghuo reagent adds right amount of auxiliary materials such as dextrin, sucrose, makes granule, drying, and packing is promptly.
Tablet: qinghuo reagent adds right amount of auxiliary materials such as dextrin, Pulvis Talci, magnesium stearate, makes granule, tabletting, promptly.
Capsule: qinghuo reagent adds right amount of auxiliary materials such as dextrin, makes granule, and is encapsulated, promptly.
Embodiment 6
Rhizoma Alismatis 550g Rhizoma Atractylodis Macrocephalae 320g Poria 340g Pericarpium Citri Reticulatae 250g Rhizoma Pinelliae 310g
Fructus Ligustri Lucidi 450g Herba Ecliptae 460g Flos Chrysanthemi 420g Radix Achyranthis Bidentatae 360g Radix Glycyrrhizae 250g
More than ten flavor medicines, decoct with water 2 times, 3 hours for the first time, the 2nd time 2.5 hours, collecting decoction filters, and filtrate is concentrated into relative density 1.30 (90 degrees centigrade), add 3 times of amount ethanol, get supernatant and reclaim ethanol, be condensed into relative density 1.50 (90 degrees centigrade) clear paste.Granule: qinghuo reagent adds right amount of auxiliary materials such as dextrin, sucrose, makes granule, drying, and packing is promptly.
Tablet: qinghuo reagent adds right amount of auxiliary materials such as dextrin, Pulvis Talci, magnesium stearate, makes granule, tabletting, promptly.
Capsule: qinghuo reagent adds right amount of auxiliary materials such as dextrin, makes granule, and is encapsulated, promptly.
Claims (4)
1, a kind ofly treat dizzy Chinese medicine preparation, it is characterized in that its pharmacodynamic raw materials consists of:
Rhizoma Alismatis 100-550 part Rhizoma Atractylodis Macrocephalae 50-320 part Poria 50-340 part Pericarpium Citri Reticulatae 40-250 part
Rhizoma Pinelliae 60-310 part Fructus Ligustri Lucidi 80-450 part Herba Ecliptae 70-460 part Flos Chrysanthemi 80-420 part
Radix Achyranthis Bidentatae 50-360 part Radix Glycyrrhizae 40-250 part.
2, a kind ofly treat dizzy Chinese medicine preparation, it is characterized in that its pharmacodynamic raw materials consists of:
Rhizoma Alismatis 150-350 part Rhizoma Atractylodis Macrocephalae 80-220 part Poria 80-220 part Pericarpium Citri Reticulatae 50-150 part Rhizoma Pinelliae Preparata
80-210 part Fructus Ligustri Lucidi 90-250 part Herba Ecliptae 90-260 part Flos Chrysanthemi 150-220 part Radix Achyranthis Bidentatae
80-160 part Radix Glycyrrhizae 40-150 part.
3, a kind ofly treat dizzy Chinese medicine preparation, it is characterized in that its pharmacodynamic raw materials consists of:
125 parts of 187.5 parts of Pericarpium Citri Reticulataes of 187.5 parts of Poria of 312.5 parts of Rhizoma Atractylodis Macrocephalaes of Rhizoma Alismatis
225 parts of Flos Chrysanthemi 200g of 225 portions of Herba Ecliptaes of 187.5 parts of Fructus Ligustri Lucidi of the Rhizoma Pinelliae
100 parts in 125 portions of Radix Glycyrrhizaes of Radix Achyranthis Bidentatae.
4, the preparation method of any preparation of claim 1-3 is characterized in that, process following steps: get raw material, decoct with water 2 times, 0.5-3 hour for the first time, the 2nd time 0.5-2.5 hour, collecting decoction, filter, filtrate is concentrated into relative density 1.05-1.30, adds 1-3 and doubly measures ethanol, gets supernatant and reclaims ethanol, be condensed into relative density 1.20-1.50 clear paste, qinghuo reagent adds that the medicine acceptable carrier makes any pharmaceutically useful preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410074042 CN1283289C (en) | 2004-09-01 | 2004-09-01 | Traditional Chinese medicine preparation for treating vertigo and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410074042 CN1283289C (en) | 2004-09-01 | 2004-09-01 | Traditional Chinese medicine preparation for treating vertigo and preparation method thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610000652 Division CN1824102A (en) | 2004-09-01 | 2004-09-01 | Chinese medicinal preparation for treating giddiness and its quality control method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1628830A CN1628830A (en) | 2005-06-22 |
| CN1283289C true CN1283289C (en) | 2006-11-08 |
Family
ID=34846904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410074042 Expired - Lifetime CN1283289C (en) | 2004-09-01 | 2004-09-01 | Traditional Chinese medicine preparation for treating vertigo and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1283289C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102940785B (en) * | 2012-09-19 | 2014-09-24 | 包晓娜 | Traditional Chinese medicine composition for treating vertigo |
| CN103655980A (en) * | 2013-12-25 | 2014-03-26 | 孙斌 | Traditional Chinese medicine for treating randomized stagnation of phlegm type auditory vertigo |
| CN104587396A (en) * | 2015-01-15 | 2015-05-06 | 国家电网公司 | Preparation for preventing dizziness caused by power overhead operation |
| CN110007031B (en) * | 2019-04-30 | 2021-06-18 | 南京海昌中药集团有限公司 | Fingerprint detection method of glossy privet fruit roasted with liquorice juice |
| CN110927322B (en) * | 2019-11-07 | 2022-05-17 | 石药集团中奇制药技术（石家庄）有限公司 | Detection method of Huoxiang Zhengqi mixture |
| CN114487196B (en) * | 2022-01-27 | 2023-11-14 | 鲁南厚普制药有限公司 | Method for establishing HPLC fingerprint of Gastrodia elata dizzy granule and fingerprint thereof |
-
2004
- 2004-09-01 CN CN 200410074042 patent/CN1283289C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1628830A (en) | 2005-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1785371A (en) | Chinese medicinal preparation for abating child fever and its preparation method | |
| CN1283289C (en) | Traditional Chinese medicine preparation for treating vertigo and preparation method thereof | |
| CN1144803C (en) | Chinese chestnut flower flavone compound and its extraction process | |
| CN101057925A (en) | Preparation technology for 'jieguqili' capsule and its quality control method | |
| CN1689596A (en) | Hypericum perforatum extract and its preparation process | |
| CN114053337B (en) | Traditional Chinese medicine composition with effects of relieving spirit and resisting depression and preparation method thereof | |
| CN1895462A (en) | Nankang soft capsule for treating prostatitis | |
| CN1824102A (en) | Chinese medicinal preparation for treating giddiness and its quality control method | |
| CN1824245A (en) | Quality control method of bone sinew medicinal pill preparation | |
| CN103028109B (en) | Traditional Chinese medicine agent for treating Alzheimer disease | |
| CN1772084A (en) | Tongshu oral cavity refreshing tablet and its prepn | |
| CN1853688A (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof | |
| CN1931212A (en) | Medicine for preventing and treating senile dementia and its prepn and use | |
| CN1775271A (en) | Hyperfunction-inhibiting preparation and new preparing method | |
| CN101045077A (en) | Preparating method of oral solid preparation of fenugreek and its use | |
| CN1853689A (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and making method thereof | |
| CN1586612A (en) | Process for preparing granular powder for treating blood stasis disease and quality control method | |
| CN1220510C (en) | Chinese patent medicine with the functions of replenishing qi and blood and nourishing the heart to calm the mind, its preparation method and quality control method | |
| CN1319550C (en) | Preparation of traditional Chinese medicine for treating cardio vascular disease, its preparation method and quality control method | |
| CN1220509C (en) | Chinese patent medicine for curing cardiovascular disease, its preparation method and quality control method | |
| CN104623064B (en) | A kind for the treatment of osteoporosis preparation | |
| CN1176677C (en) | Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1583133A (en) | Effervescent tablets for bone diseases and their preparation | |
| CN1768775A (en) | Prescription containing sweet clover component and its formulation | |
| CN1911301A (en) | Compound medicine for treating acute/chronic gastroenteritis, and its prepn. method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SANJIN PHARMACEUTICAL CO., LTD., GUILIN Free format text: FORMER OWNER: GUILIN SANJIN BIOLOGICAL PHARMACEUTICAL CO., LTD., SANJIN GROUP Effective date: 20130424 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 541100 GUILIN, GUANGXI ZHUANG AUTONOMOUS REGION TO: 541004 GUILIN, GUANGXI ZHUANG AUTONOMOUS REGION |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130424 Address after: 541004 No. 1 Jinxing Road, Guilin, the Guangxi Zhuang Autonomous Region Patentee after: GUILIN SANJIN PHARMACEUTICAL Co.,Ltd. Address before: 541100 Guilin Avenue, the Guangxi Zhuang Autonomous Region, Xicheng District, No. 112 Patentee before: GUILIN SANJIN BIOLOG PHARMACEU |
|
| CX01 | Expiry of patent term |
Granted publication date: 20061108 |
|
| CX01 | Expiry of patent term |